Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. In the early 1960s, Ernest A. McCulloch and James E. started several experiments leading to the discovery of stem cells. It was not until much later in 1987 that exosomes were first identified in a mammalian reticulocyte (red blood cell)[1] and not until 2007 that exosome-mediated transfer of mRNAs and microRNAs was identified as a “novel mechanism of genetic exchange between cells.”[2] [Read more…]
Top 4 Most Richly Funded Exosome Startups
In recent years, exosome start-up companies have been the recipients of hundreds of millions of dollars in investor funding. Clearly, investors are feeling favorable toward companies developing exosome products and there is a growing belief that the industry is poised for growth. [Read more…]
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
-
Company demonstrates reliable production from multiple biological sources
-
These manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining efficiency
TORONTO and HAIFA, Israel, Aug. 15, 2024 — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), announces significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they are at the heart of the Company’s innovative ExoPTEN product, which is being developed for the treatment of acute spinal cord injury and glaucoma. [Read more…]
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”)
AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders.
WOBURN, Mass., Aug. 14, 2024 — Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle (“EV”) therapies to address immune and inflammatory-based dermatological disorders, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102™ for the treatment of the rare pediatric skin blistering disease DEB. [Read more…]
The Rise of Exosome Manufacturing and its Evolution
Exosomes are produced and secreted out by nearly all living cells and have been found to occur in nearly every bodily fluid. They are found abundantly in the growth medium of many cultured cells, such as B lymphocytes, dendritic cells, cytotoxic T cells, intestinal epithelial cells, neurons, oligodendrocytes, platelets, mast cells and Schwann cells. [Read more…]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 27
- Next Page »